NIKKEI 225
39,089.17 +472.07 (+1.22%) HANG SENG
18,881.28 -314.32 (-1.64%) CRUDE OIL
77.05 -0.52 (-0.67%) GOLD FUTURES
2,373.30 -19.60 (-0.82%) DOW
39,671.04 -201.95 (-0.51%) Bitcoin GBP
54,486.07 -416.45 (-0.76%)
ANAB May 2024 15.000 put
- Simply Wall St.
Industry Analysts Just Upgraded Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts By 16%
Shareholders in AnaptysBio, Inc. ( NASDAQ:ANAB ) may be thrilled to learn that the analysts have just delivered a major...
- Zacks
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates
AnaptysBio (ANAB) delivered earnings and revenue surprises of -6.49% and 57.78%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colitis (UC) with rosnilimab, our PD-1 agonist; reiterating top-line data anticipated by mid 2025 and H1 2026, respectivelyIND submissions for ANB033 (anti-CD122 antagonist) and ANB101 (BDCA2 modulator) anticipate
